Another leading risk calculator was formed from the patients enrolled as part of the European Randomised Study of Screening for Prostate Cancer (ERSPC), which developed in European population to predict PCa using PSA, DRE, prostate volume and the previous negative biopsy status [10]. This evidence concerns the gene KLK3 and Familial prostate cancer.